What does Juvenescence Limited do?
Juvenescence Limited is a clinical-stage biotech company that leverages AI to develop novel medicines targeting the core mechanisms of aging. The company focuses on treating and preventing age-related diseases, including issues related to cognition, cardio-metabolism, immunity, and cellular repair.
How much did they raise?
The company raised $76M in the first tranche of its Series B-1 funding round, led by cornerstone investor M42, with participation from existing investors.
What are their plans for the money?
Juvenescence plans to use the funds to advance its portfolio of clinical and near-clinical stage therapeutics into clinical development, potentially accelerating the delivery of treatments that extend healthy lifespan.
What have they achieved so far?
The company has already achieved significant progress with a diverse pipeline of therapeutic candidates targeting core aging mechanisms, and it has also invested in complementary AI and regenerative medicine platforms.
